Golden State Equity Partners Boosts Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Golden State Equity Partners boosted its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 19.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,454 shares of the medical equipment provider’s stock after buying an additional 239 shares during the period. Golden State Equity Partners’ holdings in Intuitive Surgical were worth $491,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Portside Wealth Group LLC grew its position in Intuitive Surgical by 8.2% in the 4th quarter. Portside Wealth Group LLC now owns 816 shares of the medical equipment provider’s stock valued at $275,000 after buying an additional 62 shares during the last quarter. Sequoia Financial Advisors LLC grew its position in Intuitive Surgical by 58.0% in the 4th quarter. Sequoia Financial Advisors LLC now owns 8,315 shares of the medical equipment provider’s stock valued at $2,805,000 after buying an additional 3,054 shares during the last quarter. Kades & Cheifetz LLC purchased a new position in Intuitive Surgical in the 4th quarter valued at $230,000. Blair William & Co. IL boosted its position in shares of Intuitive Surgical by 3.1% during the 3rd quarter. Blair William & Co. IL now owns 377,371 shares of the medical equipment provider’s stock worth $110,302,000 after purchasing an additional 11,400 shares in the last quarter. Finally, Assenagon Asset Management S.A. boosted its position in shares of Intuitive Surgical by 21.2% during the 3rd quarter. Assenagon Asset Management S.A. now owns 739,471 shares of the medical equipment provider’s stock worth $216,140,000 after purchasing an additional 129,194 shares in the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ISRG has been the topic of several research analyst reports. Jefferies Financial Group boosted their target price on shares of Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a research report on Friday, April 19th. BTIG Research boosted their target price on shares of Intuitive Surgical from $412.00 to $421.00 and gave the stock a “buy” rating in a research report on Friday, April 19th. Mizuho boosted their target price on shares of Intuitive Surgical from $350.00 to $390.00 and gave the stock a “neutral” rating in a research report on Thursday, January 25th. Royal Bank of Canada boosted their target price on shares of Intuitive Surgical from $400.00 to $432.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 24th. Finally, Raymond James boosted their target price on shares of Intuitive Surgical from $372.00 to $435.00 and gave the stock an “outperform” rating in a research report on Thursday, January 25th. Five equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $396.17.

Insider Activity at Intuitive Surgical

In other news, EVP Myriam Curet sold 5,318 shares of the company’s stock in a transaction dated Tuesday, April 23rd. The shares were sold at an average price of $370.66, for a total transaction of $1,971,169.88. Following the completion of the transaction, the executive vice president now owns 298 shares of the company’s stock, valued at approximately $110,456.68. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, CEO Gary S. Guthart sold 24,325 shares of the company’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $376.06, for a total transaction of $9,147,659.50. Following the completion of the transaction, the chief executive officer now owns 9,425 shares of the company’s stock, valued at approximately $3,544,365.50. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Myriam Curet sold 5,318 shares of the company’s stock in a transaction dated Tuesday, April 23rd. The shares were sold at an average price of $370.66, for a total transaction of $1,971,169.88. Following the transaction, the executive vice president now directly owns 298 shares of the company’s stock, valued at approximately $110,456.68. The disclosure for this sale can be found here. In the last quarter, insiders sold 249,418 shares of company stock valued at $96,300,959. 0.90% of the stock is owned by insiders.

Intuitive Surgical Trading Up 0.6 %

Shares of ISRG stock opened at $375.33 on Friday. The firm has a 50-day moving average price of $386.19 and a 200 day moving average price of $346.29. Intuitive Surgical, Inc. has a twelve month low of $254.85 and a twelve month high of $403.76. The company has a market capitalization of $133.13 billion, a price-to-earnings ratio of 67.75, a PEG ratio of 4.85 and a beta of 1.36.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The firm had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. During the same quarter in the previous year, the company posted $1.00 EPS. The firm’s revenue for the quarter was up 11.5% on a year-over-year basis. As a group, research analysts predict that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.